Tata India Pharma & Healthcare Fund-Direct Plan-Growth

Open Ended Schemes(Equity Scheme - Sectoral/ Thematic)Very High RiskISIN INF277K019A3

NAV · 06-Jul-2026

₹38.8230

+6.17%

+8.77%

1Y (CAGR)

+9.27%

3Y (CAGR)

+23.34%

5Y (CAGR)

+15.03%

Since inception (CAGR)

+13.70%

NAV history

hover for values

Risk & SIP analytics

Q1 · TOP · 3Y in category

Volatility (3y)

13.36%

Downside dev (3y)

9.32%

Max drawdown (3y)

-16.8%

Sharpe (3y)

1.26

SIP XIRR (3y)

+14.79%

SIP XIRR (5y)

+18.63%

Calendar-year returns

2020 +66.9%2021 +20.9%2022 -6.6%2023 +38.6%2024 +42.5%2025 -3.5%

Fund facts

Fund managerRajat Srivastava

AUM₹13,869 Cr

Expense ratio0.67% · 2026-05-31

TER · AMFI officialDirect 0.94% · Regular 2.25% (2026-06-30)

Launch date04-Dec-2015

Plan typeOpen Ended · Equity

Min lumpsum₹5,000

Min SIP₹100

Lock-inNone

Volatility15.35

AMCTata Asset Management Limited

Objective · The investment objective of the scheme is to seek long term capital appreciation by investing atleast 80% of its net assets in equity/equity related instruments of the companies in the pharma & healthcare sectors in India.

scheme documents ↗